ストックスクリーナーアプリを入手
0.2713
0.56%
0.0015
アフターアワーズ：
.27
-0.0013
-0.48%
前日終値:
$0.2698
開ける：
$0.2672
24時間の取引高:
1.43M
Relative Volume:
0.67
時価総額：
$4.17M
収益：
$4.71M
当期純損益:
$-11.79M
株価収益率:
-0.081
EPS:
-3.3492
ネットキャッシュフロー:
$-9.72M
1週間 パフォーマンス:
+2.96%
1か月 パフォーマンス:
-14.42%
6か月 パフォーマンス:
-76.20%
1年 パフォーマンス:
-87.26%
1日の値動き範囲:
$0.2625
$0.2899
1週間の範囲:
$0.2494
$0.2899
52週間の値動き範囲:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
名前
Ensysce Biosciences Inc
セクター
電話
(858) 263-4196
住所
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.2713 | 4.17M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc (ENSC) 最新ニュース
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - lwvtexas.org
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule - Stock Titan
Ensysce Biosciences : Corporate Overview - marketscreener.com
ENSC Advancing Testing and Expanding Potential - Yahoo Finance
Ensysce Biosciences (ENSC) Rallies +0.54% as Bulls Target $0.29 2026-05-18OBV Divergence - Newser
Ensysce Biosciences (ENSC) Crushes Q1 2026 Estimates — EPS $-0.52 Tops ViewsCFO Commentary Report - The Legal Advocate
Press Releases about Ensysce Biosciences, Inc.Common Stock - The Chronicle-Journal
Ensysce Biosciences, Inc.Common Stock (Nasdaq:ENSC) Stock Quote - The Chronicle-Journal
Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78 - MSN
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce biosciences launches formal review of strategic alternativesSEC filing - marketscreener.com
Ensysce Biosciences Launches Formal Review Of Strategic AlternativesSEC Filing - TradingView
Ensysce Biosciences : Earnings Release Q1 2026 - marketscreener.com
ENSC: Clinical milestones and new financing highlight Q1 2026 amid ongoing R&D-driven losses - TradingView
Wider Q1 loss leaves Ensysce (NASDAQ: ENSC) with limited cash runway - Stock Titan
Ensysce Biosciences (ENSC) posts Q1 2026 loss, cash squeeze and strategic review - Stock Titan
This biotech is testing an opioid designed to limit overdose risk - Stock Titan
ENSC Q1'26 Earnings: EPS estimate is (0.73) USD - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Nasdaq most active stocks: - MSN
TradingKey - TradingKey
Ensysce receives Taiwan patent for overdose protection technology - Investing.com UK
Ensysce receives Taiwan patent for overdose protection technology By Investing.com - Investing.com South Africa
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Corsicana Daily Sun
Opioid overdose-protection tech MPAR gets Taiwan patent to 2042 - Stock Titan
Sold 🍀🤞🏻 - Moomoo
$Ensysce Biosciences (ENSC.US)$ something in the milk aint clean…LG - Moomoo
Check out the stocks that are attracting the most attention and driving market activity. - ChartMill
MSN Money - MSN
Ensysce Biosciences Inc (ENSC) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):